Different radiolabelling methods alter the pharmacokinetic and biodistribution properties of Plasminogen Activator Inhibitor Type 2 (PAI-2) formsMarie Ranson, Andrew Katsifis, Paula Berghofer et al.|Nuclear Medicine and Biology|2012Cited by 4